Romidepsin
- Generic Name
- Romidepsin
- Brand Names
- Istodax
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36N4O6S2
- CAS Number
- 128517-07-7
- Unique Ingredient Identifier
- CX3T89XQBK
- Background
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
- Indication
用于在已接受至少1次既往全身治疗的患者中皮肤T-细胞淋巴瘤的治疗(CTCL)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL)
- Associated Therapies
- -
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00098527
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
FR901228 in Treating Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00098397
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-09-09
- Last Posted Date
- 2013-03-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00091195
- Locations
- 🇺🇸
High Point Regional Hospital, High Point, North Carolina, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00086827
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00084461
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT00084682
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Depsipeptide in Treating Patients With Solid Tumors
- Conditions
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019318
- Locations
- 🇺🇸
Medicine Branch, Bethesda, Maryland, United States
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-07-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00079443
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00077337
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00077194
- Locations
- 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Howard University Cancer Center at Howard University Hospital, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.